This study analyzed 135 hospitalized patients with COVID-19 in northeast Chongqing, China, to understand the clinical features and treatment of the disease. The median age of patients was 47 years, with no significant gender difference (53.3% male). Most patients had contact with people from Wuhan, and 31.9% had underlying diseases such as hypertension, diabetes, cardiovascular disease, and malignancy. Common symptoms included fever (88.9%), cough (76.5%), and fatigue (32.5%). All patients received antiviral therapy (Kaletra and interferon), and many received antibacterial therapy and corticosteroids. Traditional Chinese medicine (TCM) was used in 91.8% of patients. Severe cases had lower lymphocyte counts and higher levels of inflammatory markers compared to mild cases. Chest CT scans showed bilateral patchy shadows or ground glass opacity in all patients. The study suggests that early use of Kaletra and combination of Western and Chinese medicines may improve treatment outcomes. The 28-day mortality rate was 2.5%. The study highlights the importance of early diagnosis, supportive treatment, and the potential role of TCM in the treatment of COVID-19. Further research is needed to explore the effectiveness of Kaletra and TCM in treating the disease.This study analyzed 135 hospitalized patients with COVID-19 in northeast Chongqing, China, to understand the clinical features and treatment of the disease. The median age of patients was 47 years, with no significant gender difference (53.3% male). Most patients had contact with people from Wuhan, and 31.9% had underlying diseases such as hypertension, diabetes, cardiovascular disease, and malignancy. Common symptoms included fever (88.9%), cough (76.5%), and fatigue (32.5%). All patients received antiviral therapy (Kaletra and interferon), and many received antibacterial therapy and corticosteroids. Traditional Chinese medicine (TCM) was used in 91.8% of patients. Severe cases had lower lymphocyte counts and higher levels of inflammatory markers compared to mild cases. Chest CT scans showed bilateral patchy shadows or ground glass opacity in all patients. The study suggests that early use of Kaletra and combination of Western and Chinese medicines may improve treatment outcomes. The 28-day mortality rate was 2.5%. The study highlights the importance of early diagnosis, supportive treatment, and the potential role of TCM in the treatment of COVID-19. Further research is needed to explore the effectiveness of Kaletra and TCM in treating the disease.